- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
ACADIA Pharmaceuticals Inc
+ Add to WatchlistACAD:US
14.1890 USD 0.3990 2.89%
Share
As of 20:10:00 ET on 05/24/2013.
More on ACAD
News for ACADIA Pharmaceuticals Inc (ACAD)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Largest Nasdaq Short Interest Percent Increases as of April 30
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Acadia Gets Expedited FDA Review Path for Lead Drug
- The Top Ten Stocks for Thursday, April 11
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Biotie Considers Developing Alzheimer’s Drug on Its Own
- Largest Nasdaq Short Interest Percent Increases as of Nov. 30
- U.S. Stock Options With Biggest Changes in Implied Volatility
- The Top Ten Stocks for Nov. 27
- Acadia Surges as Parkinson’s Treatment Shows Benefit
- U.S. Stock Options With Biggest Changes in Implied Volatility
- ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Published May 20, 2013
- ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index Published May 20, 2013
- ACADIA Pharmaceuticals Prices Public Offering of Common Stock Published May 15, 2013
- ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock Published May 14, 2013
- Faruqi & Faruqi, LLP Launches An Investigation Against ACADIA Pharmaceuticals Inc. (ACAD) For Potential Breaches Of Fiduciary Published May 10, 2013
- ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results Published May 07, 2013
- ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013 Published Apr 30, 2013
- ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013 Published Apr 25, 2013
- Valeant Said to Be Near to Acquiring Bausch & Lomb Updated 2 hours ago
- Warburg Would Get Threefold Return in Bausch Transaction Updated 2 hours ago
- Siga Ruled Liable for Breaking PharmAthene Drug Contract
- Bausch & Lomb Unit Pays $33.5 Million in Misbranding Case
- Canadian Stocks Rise as Valeant Jump Offsets Slumps in Oil, Gold
- Winteam to Buy Tongjitang Medicine for $393 Million
- Mathew Martoma Will Get Documents From SEC, Judge Says
- Swiss Stocks Little Changed, After 2.8% Decline Yesterday
- European Stocks Fall for Second Day Amid Stimulus Debate
- U.K. Stocks Drop for Second Day as Investors Consider Fed
- Wockhardt Drug Filings Seen Delayed After U.S. FDA Alert
- Apple’s Tax Magic Leaves Irish Bondholders Unmoved: Euro Credit
- Murray International’s Stout Says Stocks Too Expensive
- Elan Board Unanimously Rejects $6.4B Takeover Offer
- Wockhardt Has Biggest 2-Day Drop on Record on U.S. Restrictions
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page